Presentation of a New Instrument: The Diagnostic Headache Diary

Russell, Michael Bjørn; Rasmussen, Birthe Krogh; Brennum, Jannick; Iversen, Helle K.; Jensen, Rigmor; Olesen, Jes

doi:10.1111/j.1468-2982.1992.00369.x

Cited by 208 publications

(181 citation statements)

References 9 publications

Supporting

Mentioning

176

Contrasting

Unclassified

Order By: Relevance

“…2) Submeter os indivíduos selecionados a acompanhamento especializado, monitorando-os por diário padronizado 39 . A maioria dos pacientes com cefaléias crônicas são mal examinados, maldiagnosticados e tratados inadequadamente.…”

Section: Discussionunclassified

Prevalência e custos indiretos das cefaléias em uma empresa brasileira

Vincent

Rodrigues²,

Oliveira³

et al. 1998

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

RESUMO -Funcionários de uma empresa (n=993) foram entrevistados quanto à ocorrência de cefaléias durante um período retrospectivo de 30 dias. A prevalência foi 49,8%, com frequência de 4,3±7,0 episódios e duração de 12,2±21,4 horas. Os diagnósticos baseados na classificação da Sociedade Internacional de Cefaléias, foram enxaqueca (5,5%), cefaléia do tipo tensão (CTT) episódica (26,4%), CTT crônica (1,7%) e outras cefaléias (16,2%). As mulheres foram mais acometidas e tiveram proporcionalmente mais enxaquecas que os homens. Cerca de 10% dos pacientes relataram dor suficientemente intensa a ponto de prejudicar seu desempenho no trabalho, o que representou 538,75 horas não trabalhadas. O custo indireto proporcionado pela interferência no trabalho foi estimado para cada cefaléia. O potencial prejuízo projetado à empresa devido às cefaléias é R$145,64 por funcionário, ou R$144 682,39 por ano. Como a enxaqueca é a cefaléia de maior custo, seu controle é particularmente importante no ambiente de trabalho. Há meios eficazes para reduzir sua frequência, com reflexos positivos no bem-estar e na produtividade do indivíduo. A relação custo-benefício favorece claramente a instituição de programas de prevenção e tratamento contra cefaléias crônicas. PALAVRAS-CHAVE: cefaléia, enxaqueca, epidemiologia, custos. Prevalence and indirect costs of headache in a Brazilian CompanyABSTRACT -Employees from a Brazilian oil company reserach centre (n=993) were interviewed on the occurrence of headache during a 30 days period. Headache prevalence was 49.8%, with a mean frequency of 4.3±7.0 attacks per month, lasting 12.2±21.4 hours each. According to the International Headache Society diagnostic criteria, migraine (5.5%), episodic tension-type headache (26.4%), chronic tension-type headache (1.7%) and headaches not fulfilling the criteria for such disorders (16.2%) were observed. Women suffered comparatively more headache and specifically migraine than men. The pain interfered with work productivity in 10% of the subjects, corresponding to 538.75 hours off. According to an indirect costs estimation for each headache, the company may loose up to US$125.98 per employee annually. Since among headaches migraine has the highest indirect cost, migraine prevention and treatment is particularly important at the working environment. Migraine frequency may be prevented to a large extent, resulting on positive effects in both the quality of life and productivity. The cost-benefit ratio clearly favours therapeutic and preventive programs against chronic headaches.KEY WORDS: headache, migraine, epidemiology, costs.Poucos são os indivíduos que jamais experimentam um episódio de cefaléia 1,2 . Noventa por cento dos homens e 95% das mulheres admitem ter sofrido algum tipo de dor de cabeça durante 1 Setor

show abstract

Section: Discussionunclassified

Prevalência e custos indiretos das cefaléias em uma empresa brasileira

Vincent

Rodrigues²,

Oliveira³

et al. 1998

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

show abstract

“…Other screens have also been reported to have good sensitivity and specificity. [16][17][18][19][20][21][22][23] Limitations of this study include the fact that these data are now 5 years old, although it seems unlikely that the prevalence or burden of migraine in managed care members is less today than it was when these data were collected. We also did not measure costs and did not calculate the financial burden of migraine.…”

Section: Figurementioning

confidence: 99%

Prevalence and Burden of Illness of Migraine in Managed Care Patients

Kobak¹,

Katzelnick²,

Sands

et al. 2005

JMCP

View full text Add to dashboard Cite

“…Study by Russell et al reports that the second and third decade of life as the most common age of onset of migraine. 16 Out of 90 patients, 53 (58.88%) were females and 37 (41.12%) were males, overall incidence of migraine was found to be higher in females ratio being 1.5:1 which is the ratio found in most of the studies. 17 The reason for the preponderance in women is still unexplained.…”

Section: Safety and Tolerabilitymentioning

confidence: 63%

Evaluation of propranolol, flunarizine and divalproex sodium in prophylaxis of migraine

Bhat

Sidhu

Goyal³

2017

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

Background: Preventive treatment has an important role in the management of migraine. Propranolol and flunarizine have been used for more than two decades while, open-label, controlled studies suggest divalproex sodium may also be efficacious for migraine prevention. The objective of the study to compare efficacy and safety of propranolol, flunarizine and divalproex sodium in patients for migraine prophylaxis.Methods: Following approval from IEC a 12-week randomized, open, comparative study was carried out at the outpatient department of Medicine. Patients between 18 to 65 years, with history of 3 to 12 migraines a month (IHS) for six months were included. Patients were divided into three groups of 30 patients to receive - propranolol 20 to 160mg/day; flunarizine 5 to 10mg/day or divalproex sodium 250 to 750mg/day, for three months.Results: Total 90/116 patients completed the study. No significant differences were found between the groups with regards to mean age or other baseline migraine features. All the drugs significantly decreased the frequency, duration and severity of migraine (P<0.001). There is no statistically significant difference between propranolol, flunarizine and divalproex sodium for any of the efficacy parameters. All the three treatments were well-tolerated and safe.Conclusions: All the three study drugs were equally effective with an acceptable tolerability profile, Divalproex sodium group showed more side effects, none of which were serious. However, further studies with larger number of patients and longer duration of treatment are recommended.

show abstract

Presentation of a New Instrument: The Diagnostic Headache Diary

Cited by 208 publications

References 9 publications

Prevalência e custos indiretos das cefaléias em uma empresa brasileira

Prevalência e custos indiretos das cefaléias em uma empresa brasileira

Prevalence and Burden of Illness of Migraine in Managed Care Patients

Evaluation of propranolol, flunarizine and divalproex sodium in prophylaxis of migraine

Contact Info

Product

Resources

About